Quick Facts

• May be used to assist in the management of symptoms associated with functional gastrointestinal disorders.
• May be indicated for the symptomatic relief of conditions such as biliary or renal colic.
• Its use is associated with a potential reduction in certain body secretions, such as saliva and stomach acid.

---

What Hyoscyamus Treats: Main Uses and Benefits

Hyoscyamus, containing the active agents hyoscyamine and scopolamine, may be employed to help manage certain symptoms related to various conditions. Its application includes providing symptomatic relief for functional gastrointestinal disorders, such as those seen in irritable bowel syndrome (IBS) or mild dsyenteries. The medication may also be an adjunctive treatment to help manage visceral spasms and related cramps in conditions like cystitis, or for symptomatic relief of biliary and renal colic.

In a separate therapeutic domain, the component scopolamine is specifically used to prevent symptoms associated with motion sickness and may be used in the hospital setting to manage or treat postoperative nausea and vomiting (PONV). Additionally, hyoscyamine may be used to help reduce the amount of secretions in the body, which can involve saliva, respiratory secretions, or stomach acid output.

Regulatory References

1. NIH MedlinePlus guidance

Who Can and Cannot Use Hyoscyamus?

Eligibility for using Hyoscyamus agents is strictly defined by regulatory documents, focusing on potential risks associated with its anticholinergic properties.

Contraindicated Populations (Must Not Use)

Use is contraindicated (absolutely prohibited) in individuals diagnosed with:

• Glaucoma (or risk of narrow-angle closure).
• Obstructive Disease of the gastrointestinal or urinary tracts (e.g., prostatic hypertrophy, paralytic ileus).
• Myasthenia Gravis.
• Severe Ulcerative Colitis or Toxic Megacolon.

Age and Condition-Based Restrictions

Population Group	Regulatory Status
Pediatric Use (Under 12)	Generally not recommended due to increased susceptibility to toxic effects.
Older Adults (Geriatric)	Use requires caution due to heightened risk of anticholinergic side effects and potential renal impairment.
Renal/Hepatic Disease	Use requires caution due to the drug’s excretion by the kidneys and the need for close monitoring.
Pregnancy	Classified as FDA Category C; use only if clearly needed.
Nursing Mothers	Caution should be exercised as the active agent is excreted in human milk.

Eligibility is limited for populations with cardiovascular conditions (e.g., cardiac arrhythmias, coronary heart disease) and those exposed to elevated environmental temperatures, necessitating caution as mandated by official labeling.

Interactions with other medicines and products

Official regulatory documents classify interactions with Hyoscyamus components based primarily on two mechanisms: pharmacodynamic reinforcement and pharmacokinetic interference.

Pharmacodynamic Interactions

Co-administration with other agents that possess anticholinergic or antimuscarinic properties may result in additive adverse effects due to intensified cholinergic blockade. Substances officially listed in this category include Tricyclic Antidepressants, Phenothiazines, Monoamine Oxidase (MAO) Inhibitors, and certain Antihistamines. Specific medicines such as Amantadine and Haloperidol are also noted to carry this risk of additive adverse effects.

Pharmacokinetic and Timing Constraints

The anticholinergic action of Hyoscyamus can cause a reduction in gastrointestinal motility, which may decrease the absorption of other oral medications taken at the same time. This is particularly relevant for products like antacids, which may interfere with Hyoscyamus absorption. Regulatory documents advise a mandatory timing rule to separate the administration of oral antacids and Hyoscyamus components. Furthermore, co-administration with alcohol may potentiate central nervous system effects, such as confusion and drowsiness.

Population-Specific Cautions

Official labeling indicates that interactions leading to CNS effects are more likely to occur and require greater caution in geriatric patients and individuals with impaired renal or hepatic function.

The action of Hyoscyamus is rooted in its mechanism of blocking nerve signals that regulate involuntary functions, a characteristic known as anticholinergic blockade. The drug's active ingredients are tropane alkaloids that engage mechanisms leading to two core physiological consequences: muscle tone reduction and reduced fluid output.

Targeting Muscarinic Receptors to Block Parasympathetic Signaling

The mechanism initiates at the molecular level by the alkaloids acting as non-selective competitive antagonists on all five subtypes of the Muscarinic Acetylcholine Receptors ( mAChRs). By occupying the receptor site, the drug prevents the body's natural signaling molecule, acetylcholine ( ACh), from triggering activation. This fundamentally interrupts the nerve impulses of the parasympathetic nervous system at the neuroeffector junction.

Inhibiting the Smooth Muscle Contraction Pathway

This blockade directly impacts the M3 receptors found on smooth muscle cells throughout the gastrointestinal, biliary, and genitourinary tracts. Preventing ACh from binding effectively shuts down the molecular cascade that relies on M3 activation to mobilize intracellular calcium. The resulting inability to receive the contraction signal leads to a state of sustained muscle relaxation, which results from the reduction of cholinergic signaling to smooth muscle.

Dampening Nerve-Driven Glandular Secretion

The same M3 receptor antagonism applies to the exocrine glands, which are heavily regulated by cholinergic input. By suppressing the nerve-driven signal for fluid release, the mechanism interrupts the signal cascade mediated by excessive cholinergic activity on the secretory systems. This action results in a reduction in glandular fluid output, influencing processes such as saliva, gastric, and intestinal fluid production.

Hyoscyamus-derived agents are administered via several distinct routes, including oral (immediate-release, extended-release, and liquid forms), sublingual, parenteral (IV, IM, SC injection), and transdermal patch systems. The specific route and form depend on the active agent and the intended use pattern.

The oral dosing of Hyoscyamine is typically 0.125 mg to 0.25 mg per dose for immediate-release forms, with a maximum of 1.5 mg per 24 hours. These oral forms are generally taken 30 to 60 minutes prior to meals and at bedtime. Extended-release tablets (e.g., 0.375 mg) are scheduled every 12 hours. For Hyoscine Butylbromide, oral doses are typically 10 mg to 20 mg up to four times daily, but this use is limited to short-term, intermittent treatment and is not for continuous daily use.

Administration requires specific handling: tablets that are not designed to dissolve in the mouth must be swallowed whole and must not be crushed or chewed. For older adults using Hyoscyamine, the dose is selected cautiously, often starting at the lowest end of the range. The Scopolamine transdermal system is applied as one patch only to the hairless area behind the ear and provides continuous delivery for up to 72 hours. Intravenous Hyoscine Butylbromide is administered slowly and may be diluted with standard solutions like 0.9% sodium chloride.

Research Evidence / Overview of Studies for Hyoscyamus

The clinical research available for agents derived from Hyoscyamus (primarily scopolamine and hyoscyamine) is focused on the areas of health where these agents are studied in relation to involuntary muscle movement and glandular secretions. The evidence base includes both modern, high-quality reviews for certain uses and older clinical trial data for others.

---

Evidence for Preventing Postoperative Nausea and Vomiting (PONV)

Research exploring how symptoms change over time has focused on scopolamine's evaluation in the immediate recovery period following surgery and anesthesia. The available evidence includes systematic reviews and large meta-analyses that pool data from numerous short-term randomized controlled trials (RCTs).

The main outcomes measured were the incidence of nausea and vomiting after surgery. Findings describe patterns observed in the studies that contributed to understanding the measured risk of experiencing these outcomes. Research explored whether patterns of administration may be linked to variations in the measured outcomes. Research explored how specific study factors may impact the balance of measured outcomes across diverse surgical settings.

---

Evidence for Preventing Motion Sickness

Research has explored scopolamine in the context of preventing motion sickness, a condition characterized by fluctuating or episodic manifestations. The evidence includes controlled human laboratory studies and Randomized Controlled Trials (RCTs) involving healthy adult volunteers.

In these studies, researchers monitored the severity and frequency of symptoms such as dizziness and nausea. Data show patterns related to a lower incidence of measured symptoms when the agent was administered before the motion stimulus began. Studies explore specific areas that researchers evaluate alongside the observed outcomes.

---

Evidence for Managing Visceral Spasms and Hypermotility

Hyoscyamus extracts research examined in research exploring how symptoms change over time in conditions such as functional gastrointestinal disorders (IBS) and acute visceral colic. The research examined adult patients and focused on patient-reported outcomes describing perceived discomfort, including pain and cramping.

Some trials described patterns observed in the studies where changes in symptoms of physical discomfort were monitored over defined time intervals. However, the evidence quality varies across studies due to methodological differences and the reliance on older trial designs.

---

What Is Still Uncertain About Hyoscyamus Research

Long-term effects are not fully established for functional gastrointestinal disorders, and research provides context but not individual predictions regarding extended use. Furthermore, data for certain groups remain insufficient in the primary regulatory-cited evidence base, and sample sizes were modest in some key studies, which may limit the results' applicability.

Key Studies & References Hyoscyamine Drug Information

Common questions about Hyoscyamus (FAQ)

---

Q: How long does Hyoscyamus stay in the body's system?

Regulatory documents indicate that the half-life (the time required for half the active substance to be eliminated) of hyoscyamine sulfate is generally reported to be approximately 2 to 3.5 hours. Most of the drug is typically described as being excreted in the urine within the first 12 hours. This timeframe can vary depending on the specific formulation being used.

---

Q: What is the general difference between Hyoscyamus and Atropine?

Hyoscyamus is the name for the plant extract source, while atropine is one of the isolated tropane alkaloids that can be found in the plant, along with hyoscyamine and scopolamine. Agents derived from both Hyoscyamus and Atropine are classified in the same pharmacological class because they both work by blocking certain nerve signals.

---

Q: Is Hyoscyamus the same as scopolamine?

No, they are not the same. Hyoscyamus refers to the plant (Hyoscyamus niger) from which the active ingredients are derived. Scopolamine (also known as hyoscine) is an isolated chemical compound derived from the plant, which is described in official product information as being used in pharmaceuticals.

---

Q: What is the difference between Hyoscyamus and Belladonna?

Hyoscyamus and Belladonna are two distinct plants that both contain active chemical compounds known as tropane alkaloids. Both plants contain active compounds that function similarly by blocking certain nerve impulses, leading to their shared pharmacological classification.

---

Q: Are there different forms of Hyoscyamus medication available (e.g., tablet, liquid)?

Official labeling confirms that Hyoscyamus-derived agents are available in several different forms. These include oral options (immediate-release tablets, extended-release, and liquid), as well as sublingual tablets, parenteral (injectable) solutions, and transdermal patch systems.

---

Q: What is the maximum duration of use typically described in official guidelines for Hyoscyamus?

For certain Hyoscyamus agents, such as hyoscine butylbromide, official product information indicates that use is strictly limited to short-term, intermittent treatment. For agents without a specific short-term restriction, the duration is determined by the condition being addressed and is not defined by a maximum limit in general labeling.

---

Q: Is Hyoscyamus a natural or synthetic substance?

The medicinal compounds are tropane alkaloids derived from the poisonous plant Hyoscyamus niger (Black henbane), making the source natural. These compounds are extracted from the plant and processed into standardized pharmaceutical agents for medical use.

---

Q: How quickly does Hyoscyamus usually start working?

Specific time frames for the onset of effect are not typically detailed across all regulatory documents. However, official information describes the active ingredient hyoscyamine sulfate as being readily absorbed into the bloodstream after administration.

---

Q: How long do the effects of Hyoscyamus typically last?

The duration of the therapeutic effect is closely linked to the drug's half-life, which for the immediate-release hyoscyamine component is around 2 to 3.5 hours. Certain formulations, such as extended-release tablets or patches, are specifically designed to provide a longer duration of effect.

---

Q: What is the official safety classification of Hyoscyamus?

In the United States, Hyoscyamus derivatives are classified as prescription-only medications. This means they require a prescription from a licensed healthcare provider for use. In other regulatory regions, such as Australia, they are also classified as prescription-only medicines (Schedule 4).

---

Q: Why is Hyoscyamus sometimes used for bladder spasms?

Official information confirms that the active component hyoscyamine is used to relieve cramps or spasms of the urinary tract, which can be caused by infections or procedures. This use is based on its primary function as an antispasmodic agent that reduces involuntary muscle movement.

---

Q: Is it normal to have blurred vision when first starting Hyoscyamus?

Blurred vision is listed in official product information as a common adverse reaction associated with these agents. Due to this potential effect, official warnings advise caution with activities requiring mental alertness, such as driving.

---

Q: What is the purpose of Hyoscyamus in combination medications?

In combination products, the hyoscyamus-derived component, such as hyoscyamine, is included to act as an antispasmodic. Its purpose is to help relieve muscle cramps or spasms, particularly those occurring in the digestive tract or the urinary system.

---

Q: Is Hyoscyamus used to treat symptoms of Parkinson's disease?

Official government monographs for the active compound hyoscyamine document its use to control some of the symptoms of Parkinson’s disease.

---

Q: Is Hyoscyamus a controlled substance?

The primary components of Hyoscyamus, such as hyoscyamine, are typically classified as prescription-only medicines. They are not generally scheduled as a controlled substance under the U.S. Controlled Substances Act.

---

Q: Where can I find authoritative information on Hyoscyamus research studies?

Authoritative information on clinical research can be accessed through government-run resources. These include the National Institutes of Health (NIH) literature database (like PubMed) and official regulatory websites such as the FDA/DailyMed.

---

Q: Does using Hyoscyamus make you more sensitive to sunlight?

Official warnings state that these agents may decrease sweating. Official warnings require caution regarding exposure to heat, as the reduced sweating associated with the drug may contribute to a risk of heat prostration or heat stroke.

---

Q: Does Hyoscyamus have any effect on sleep patterns?

Drowsiness is listed in official adverse reaction sections as a common side effect of the medicine. Its anticholinergic action can potentially affect rest by contributing to central nervous system effects in sensitive individuals.

---

Q: Is Hyoscyamus listed on the WHO Model List of Essential Medicines?

Yes, its derivative hyoscine (scopolamine) is included in the WHO Model List of Essential Medicines. It is listed in the context of its use as an anti-emetic, a medicine used to prevent nausea and vomiting.

---

Q: What happens if a dose of Hyoscyamus is missed?

Regulatory information typically states that a missed dose should be taken at the earliest time possible. However, the instructions caution against taking two doses at the same time to compensate for a missed dose.

How to Store and Dispose of Hyoscyamus?

The storage of Hyoscyamus products is strictly defined by regulatory documents to maintain stability and prevent unauthorized access.

Mandatory Storage Conditions

Official labeling requires the medicine to be stored in a cool dark place or a cool and dry place, with some products specifying the temperature must remain below 86 F (30 C). This protects the product from light, heat, and moisture.

Packaging and Child Safety

Containers must be closed tightly after use, and the product should not be used if the capseal or blister seal is broken. A universal requirement is to store the medicine strictly out of reach of children.

Disposal Instructions

Official regulatory documents do not provide specific household disposal instructions. In the event of accidental overdose, instructions direct users to get medical help or contact a Poison Control Center.